Core Vct I Share Discussion Threads

[the chairman elect] 01/2/2023 11:50

Some great shells around ATMO

[hedgehog 100] 30/1/2023 18:32

Hedgehog 100 26 Jul '22 - 16:50 - 11646 of 12008 Edit 0 1 0
"Rockpool Acquisitions (ROC) 4.5p Market cap. £573K. ...
ROC has about £950K. cash, and extremely low cashburn.
ROC's large discount at the moment to its cash, despite this extremely low cashburn, looks like a temporary discrepancy - and one that is gradually being addressed by ROC's share price rise, as the market wakes up to the opportunity."


ROC was my last tip on this thread, 6 months ago.

Since then it's been suspended (at 4.7p) for an intended RTO (reverse takeover) at 7.86p:-


I.e. a 74.67% premium to my tip price.


Now it's time for my follow up tip:-

Newmark Security (NWT) 44p Market cap. £4.12M.





NWT's finish up at 44p today is now its highest closing price since November 2021.

And from the legendary Jesse Livermore:-

"Buy rule:
Go long when a stock hits a 50-week high"



NWT's interim results are due tomorrow, for the period May-October 2022, and the company has returned to profitability etc. since its full year end last April.

[the chairman elect] 30/1/2023 09:44

After the w/e [change of rig staff by FTSE100 SHELL?!?!?] a strong start to share trading over @ LSE:DELT

[the chairman elect] 30/1/2023 08:20

STOCK WATCH @ LSE:CYAN [lovely looking chart]

[christmasworker] 28/1/2023 13:59

He deletes his posts after 1000 and so hopes no one can
Remember the carp he posted
Sadly everyone does

[the chairman elect] 26/1/2023 09:45

STOCK WATCH

LSE:DELT

North sea GAS play currently drilling with FTSE100 SHELL namely LSE:DELT - the DELT chart potentially starting to look bullish [higher lows and higher highs]

[the chairman elect] 26/1/2023 07:33

United Oil and Gas plc / LSE:UOG

FY 2022 Trading and operations update and guidance for 2023

United Oil & Gas Plc (AIM: "UOG"), the full-cycle oil and gas company with a portfolio of production, development, exploration and appraisal assets , issues the following trading and operations update summarising recent operational activities, providing trading guidance in respect of the financial year to 31 December 2022, and initial guidance for 2023. This is in advance of the Company's audited full year results which will be released in April 2023. The information contained herein has not been audited and may be subject to further review and amendment.

United Chief Executive Officer, Brian Larkin commented:

"Operationally 2022 was a very active year for the Company with an extensive work programme executed in Egypt, generating good operational cashflow despite mixed drill results. Over the three years that United has held Abu Sennan, the production base has generated material cashflows for the business. As the asset matures, it is transitioning to a phase in its development where operations are focused on maintaining and extending long term production rates to generate operational cashflows for many years to come. Egypt remains an integral part of our business providing operational cashflow which supports the wider asset portfolio of the Company and our strategy to grow through M&A.

"In Jamaica, the farm-out of our high impact exploration licence with 2.4 billion barrels of unrisked mean prospective oil resource is picking up pace with a timetable for receipt of indicative offers due in Q2 2023. We continue to build on our excellent track record of active portfolio management, adding value to our assets and monetising them in excess of our investment, as seen most recently with the sale of the Maria discovery.

"In line, with our continued focus on good capital allocation and the recognition of the value disconnect between the business valuation and the share price, United intends to seek the requisite approvals from shareholders at our 2023 AGM to allow for a limited buyback programme, should this be the best use of capital at the time.

"I am excited about the potential for the Company as the fundamentals of the business remain solid, and we remain committed to our growth ambitions with the focus on new ventures in the Greater Mediterranean and North Africa regions."

[the chairman elect] 25/1/2023 09:15

Darktrace / LSE:DARK growth story seen intact, Morgan Stanley upgrades to buy, PT 410p

[the chairman elect] 25/1/2023 07:50

Noirua24 Jan '23 - 12:22 - 12001 of 12002

Tulla Resources are now not far short of selling its interest in most of the gold tenements at Norseman.



Could you please post anything further including any links over on the TUL thread?

[noirua] 24/1/2023 12:22

Tulla Resources are now not far short of selling its interest in most of the gold tenements at Norseman.

[noirua] 24/1/2023 12:20

Power Metal POW - Red Rock RRR.
ASX or AIM: NBGC - Australian Gold Price Charts:
3-day chart:
Long Term chart: Live gold price back to 2015 in AUD:

The gold price in Aussie dollars is now close to an all-time high point. This should point to an IPO of NBGC very shortly.

[the chairman elect] 24/1/2023 10:35

STOCK WATCH over @ AIM listed KODAL MINERALS / LSE:KOD //// looking very good on the charts over @ KOD

[the chairman elect] 24/1/2023 07:50

Roquefort Therapeutics plc / LSE:ROQ

MDK Oncology Antibodies Demonstrate In-Vivo Safety

Development milestone achieved

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high growth, high value oncology market is pleased to announce the ROQ-A1 and ROQ-A2 Midkine ("MDK") antibody programs, targeting metastatic breast cancer and metastatic lung cancer, have successfully demonstrated in vivo safety in pre-clinical development programs carried out by leading cancer research groups.

As stated in the Company's announcement of 9 January 2023, Roquefort Therapeutics has recently signed partnership agreements and commenced pre-clinical development programs with leading academic cancer research groups at the Olivia Newton-John Cancer Research Institute (La Trobe University), Lowry Cancer Research Centre (University of New South Wales), Hawkins Laboratory Biochemistry and Genetics (La Trobe University) and the School of Medical Sciences (University of Sydney).

ROQ-A1 and ROQ-A2 are the latest patented humanised antibody medicines designed by Roquefort Therapeutics to target the novel MDK target prevalent in hard-to-treat cancers. In laboratory experiments, ROQ-A1 and ROQ-A2 bind highly specifically to the MDK receptors in cancer cells to kill cancers in vitro.

The MDK antibody programs targeting metastatic breast cancer and metastatic lung cancer commenced in Q4 2022 at La Trobe University, Melbourne in the Olivia Newton-John Cancer Research Institute and Hawkins Laboratory respectively and have now successfully reached the first pre-clinical drug development milestone. Metastatic breast cancer and metastatic lung cancer were chosen because of high patient mortality rates (~70% at five years) and prevalence of resistant MDK subtypes which can reduce effectiveness of existing therapies. Therefore, Roquefort Therapeutics is pleased that both ROQ-A1 and ROQ-A2 have demonstrated a good safety profile in validated in vivo models. These milestones were completed on schedule and within budget.

Both MDK antibody programs will now progress into in vivo pre-clinical efficacy studies to assess cancer killing ability in primary and metastatic breast cancer and lung cancer. The Company will update the market on the results of these efficacy studies as they progress.

Ajan Reginald, Chief Executive Officer of Roquefort Therapeutics, said:

"We have started 2023 with significant momentum successfully completing these initial pre-clinical development milestones on schedule and within budget. The ROQ-A1 and ROQ-A2 antibodies are valuable assets that fit the established Big Pharma paradigm of treating cancer with novel antibody therapeutics. Therefore, we are pleased that both programs have shown the good safety profile that is particularly attractive for innovative cancer medicines targeting novel targets such as Midkine. Both programs will now progress rapidly into in vivo pre-clinical efficacy testing. The siRNA, MK cell therapy and Midkine oligonucleotide programs are also progressing well and are expected to complete development milestones in Q1, which we will update the market on in due course."

[christmasworker] 21/1/2023 14:18

From the BB house comes this weeks Webble weveew
Wrks is nailed, down 20pc on Friday

😬
Way aye man as we say in Newcastle


Not much longer webble watchers

[christmasworker] 21/1/2023 14:17

From the BB house comes this weeks Webble weveew
Wrks is nailed, down 20pc on Friday

😬
Way aye man as we say in Newcastle

[noirua] 21/1/2023 11:10

QBT -
Full of bullish posts by holders. Should manage 3p short term IMHO.

[the chairman elect] 21/1/2023 09:30

KODAL MINERALS //// LSE:KOD

"our valuation to around 0.88p/s representing a 138% uplift on today’s share price. We therefore rate the shares as a buy on the assumption the deal will consummate."

SP Angel acts as financial advisor and broker to Kodal Minerals.

Conclusion: The Hainan deal is extraordinary in that Kodal are entitled to their 49% of the profit from the joint venture through their simple addition contribution of the project.

We assume the joint venture will pay all related costs out of the $100m of cash provided by Hainan. There does not appear to be any preferential repayment of capital to Hainan.

We are not aware of any expensive royalty, streaming or peculiar loan note arrangements draining the cash flow making this possibly the simplest and cleanest deal we have seen.

SP Angel acts as financial advisor and broker to Kodal Minerals.

So my take on all of this is that KOD could well go on and hit 1p+

KOD could even go higher such as 2p+ as LITHIUM prices are going through the roof plus share price ANGEL have not taken into account the GOLD projects!

[the chairman elect] 19/1/2023 10:30

Kodal Minerals* (KOD LN) – BUY – Hainan Mining agrees to fund Kodal’s Bougouni lithium project for $100m + $17.75m subscription in shares at 0.5p

Conclusion: The Hainan deal highlights the desperation of lithium processors and their client Gigafactories to lock in lithium supply. Kodal’s decision to go for a quick 12-month DMS plant has attracted >$100m of financing with a don’t-spare-the-horses deal to get lithium concentrates to China for further processing. This is a great deal for Kodal and is also a great deal for Hainan which is locking in yet another supply source for China Inc.

*SP Angel acts as financial advisor and broker to Kodal Minerals.

[the chairman elect] 19/1/2023 08:30

Kodal Minerals Plc / Index: AIM / Epic: KOD / Sector: Mining



Major funding package for development of the Bougouni Lithium Project:

US$100 million (£82 million) to be invested into Project Company and

US$17.75 million (£14.6 million) subscription for ordinary shares in Kodal; and

proposed sale of Bougouni West Project for a consideration of £2 million in cash



Kodal Minerals, the mineral exploration and development company focused on lithium and gold assets in West Africa, is pleased to announce it has agreed a conditional funding package of US$117.75 million which will provide full financing for the development and commencement of production at the Bougouni Lithium Project in Mali and support a major exploration and development programme.



The funding package has been agreed with Hainan Mining Co. Limited ("Hainan" or "Hainan Mining") and its wholly owned UK-incorporated subsidiary Xinmao Investment Co. Limited ("Xinmao" and together the "Hainan Group"). Hainan is a subsidiary of Fosun International Limited ("Fosun") and is the industrial platform for mining and resources within Fosun. The Hainan Group are highly experienced mining and development professionals and will be working in partnership with Kodal which will continue to provide the Mali and project expertise to develop the Bougouni Lithium Project ("Bougouni Project", "Bougouni" or the "Project").



Highlights:



· US$100 million committed to Kodal's newly incorporated UK subsidiary, Kodal Mining UK Limited ("KMUK"), by the Hainan Group to, inter alia, acquire 51% of KMUK to finance the construction of the mine at the Bougouni Lithium Project.

· US$17.75 million equity subscription by Hainan Group into Kodal at a price of 0.5p per share, being a premium of approximately 100% to the previous 10-days' VWAP (the "Subscription").

· KMUK would be fully funded for the US$65 million capital cost of the Dense Media Separation ("DMS") development scenario at Bougouni and is targeting delivery of first production within 12 months of receipt of funds.

· The additional funds received by KMUK beyond the DMS funding will be directed to expansion activities to increase the Bougouni Project JORC compliant resource inventory currently at 21Mt @1.11% Li2O and extend production beyond the initial four-year mine life.

· The US$17.75 million raised from the Subscription will be used to advance the Company's portfolio of gold exploration assets in Mali and Cote d'Ivoire, as well as the assessment of new exploration and development opportunities in West Africa.



Closing of the funding transactions is conditional on approval of certain authorities and regulators in China.



Bernard Aylward, CEO of Kodal Minerals, commented: "This is a great outcome for Kodal following a competitive and complex process to ensure we received appropriate recognition for the underlying value of this asset.



"We are very pleased to welcome the Hainan Group as investors into Kodal and as partners for the development of the Bougouni Lithium Project. This investment provides us with a great opportunity to fast track to production of spodumene concentrate in a very strong market. The level of funding will allow us to fully fund the dense media separation plant with mining planned to commence at the high grade Ngoualana deposit as well as to support major drilling and exploration campaigns to discover and define additional lithium mineralisation to seek to increase the life of the mining operation at Bougouni.



"The Hainan Group have completed extensive due diligence of the Bougouni Project and confirmed the potential of this quality project leading to this new partnership.



"The lithium sector remains very buoyant with high demand and market prices for spodumene concentrate. The demand is supported by the increasing take-up of electric vehicles ('EVs') and the demand for secure supply is very high. Kodal will be looking to complete an off-take agreement for the amount of product that it is free to sell outside of existing arrangements and will also review the potential to become involved in downstream processing to enhance the value of the product if viable."



Liu Mingdong, Chairman of Hainan Mining, commented : "This investment in Kodal and Kodal Mining UK Ltd is in line with Hainan Mining's strategy of improving the level of resource and feedstock security, and commencing the building of our lithium hydroxide supply chain. It is a milestone for Hainan Mining's African footprint and globalisation. We are looking forward to working closely with our partner and jointly developing the Bougouni Lithium Project in an effective way, aiming to start production and reach full scale operations as quickly as possible and create value for both partners shareholders and the people of Mali."

[noirua] 18/1/2023 09:13

QBT Quantum Blockchain moving up this morning.
RNS today: Quantum Blockchain Technologies Plc Altcoins Opportunities